Study identifier:N13
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
SYNCHRONISE: Esomeprazole 20 mg once daily for relief of upper gastrointestinal Symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs in Dutch General Practice: The influence of Risk-factors for NSAID-associated GI damage on sympton response
Heartburn
-
No
-
All
1220
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|